個人著作:

1.Kao, C. H., Liu, C. T., Lin, H., Huang, Y. C., Lan, J., Ou, Y. C., ... & Wu, C. H. (2022). Case report: Durable response after pembrolizumab in combination with radiation-induced abscopal effect in platinum-refractory metastatic endometrial clear cell carcinoma. Frontiers in Immunology, 13, 1079253.

2.Kao, C. H., Lin, H., Liu, C. T., Ou, Y. C., ... & Wu, C. H. (2023) Research article: “Real-world efficacy and safety of low-dose pembrolizumab in patients with advanced and refractory gynecologic cancers” Journal of the Formosan Medical Association, 2024, 123.4: 487-495. (SCI journal, IF= 3.1)

3.Kao, C. H., Lin, H., Ou, Y. C., Fu, H. C., Tsai, C. C., & Wu, C. H. (2026) Research article: Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: a real-world analysis. Frontiers in Immunology, 16, 1739447.

回上一頁